Ten years of sirolimus therapy in orthotopic liver transplant recipients

G. W. Neff, M. Montalbano, A. G. Tzakis

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.

Original languageEnglish
JournalTransplantation Proceedings
Volume35
Issue number3 SUPPL.
DOIs
Publication statusPublished - May 2003

Fingerprint

Sirolimus
Liver
Calcineurin
Therapeutics
Graft Rejection
Allografts
Hepatocellular Carcinoma
Steroids
Transplant Recipients
Transplants
Kidney

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Ten years of sirolimus therapy in orthotopic liver transplant recipients. / Neff, G. W.; Montalbano, M.; Tzakis, A. G.

In: Transplantation Proceedings, Vol. 35, No. 3 SUPPL., 05.2003.

Research output: Contribution to journalArticle

@article{11ef085e8301414292636bb2714299cc,
title = "Ten years of sirolimus therapy in orthotopic liver transplant recipients",
abstract = "Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.",
author = "Neff, {G. W.} and M. Montalbano and Tzakis, {A. G.}",
year = "2003",
month = "5",
doi = "10.1016/S0041-1345(03)00217-3",
language = "English",
volume = "35",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Ten years of sirolimus therapy in orthotopic liver transplant recipients

AU - Neff, G. W.

AU - Montalbano, M.

AU - Tzakis, A. G.

PY - 2003/5

Y1 - 2003/5

N2 - Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.

AB - Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.

UR - http://www.scopus.com/inward/record.url?scp=0037623421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037623421&partnerID=8YFLogxK

U2 - 10.1016/S0041-1345(03)00217-3

DO - 10.1016/S0041-1345(03)00217-3

M3 - Article

C2 - 12742498

AN - SCOPUS:0037623421

VL - 35

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3 SUPPL.

ER -